公开(公告)号：US20110009427A1

公开(公告)日：2011-01-13

申请号：US12670464

申请日：2008-07-18

Applicant: Song Li ,  Yanbo Yang ,  Junhai Xiao ,  Wu Zhong ,  Zhibing Zheng ,  Xingzhou Li ,  Yunde Xie ,  Lili Wang ,  Hongying Liu

Inventor： Song Li ,  Yanbo Yang ,  Junhai Xiao ,  Wu Zhong ,  Zhibing Zheng ,  Xingzhou Li ,  Yunde Xie ,  Lili Wang ,  Hongying Liu

IPC: A61K31/505 ,  C07D239/26 ,  A61P3/06 ,  A61P5/50 ,  A61P3/00 ,  A61P9/10 ,  A61P3/10 ,  A61P9/00 ,  A61P3/04

CPC classification number: C07D239/26

Abstract: The present invention relates to a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof. Various substituents in the formula (I) are as defined in the specification. The present invention also relates to a pharmaceutical composition comprising the compound of formula (I), the preparation method of compound of formula (I), and the use of the compound for the preparation of a medicament for treating and/or preventing human peroxisome proliferators activated receptor δ (hPPARδ)-associated diseases and risk factors.

Abstract translation: 本发明涉及式（I）化合物或其药学上可接受的盐或溶剂合物。 式（I）中的各种取代基如说明书中所定义。 本发明还涉及包含式（I）化合物，式（I）化合物的制备方法和该化合物在制备用于治疗和/或预防人类过氧化物酶体增殖物的药物中的用途的药物组合物 活化受体δ（hPPARδ）相关疾病和危险因素。

公开(公告)号：US08921563B2

公开(公告)日：2014-12-30

申请号：US13697857

申请日：2011-04-08

Applicant: Yunfeng Li ,  Rifang Yang ,  Youzhi Zhang ,  Yongzhen Li ,  Zengliang Jin ,  Peng Li ,  Li Yuan ,  Liuhong Yun ,  Nan Zhao ,  Cheng Zhang ,  Xiaodan Xu ,  Rusheng Zhao ,  Hongxia Chen ,  Rui Xue ,  Juanjuan Qin ,  Zhenzhen Wang ,  Jiazhi Yao

Inventor： Yunfeng Li ,  Rifang Yang ,  Youzhi Zhang ,  Yongzhen Li ,  Zengliang Jin ,  Peng Li ,  Li Yuan ,  Liuhong Yun ,  Nan Zhao ,  Cheng Zhang ,  Xiaodan Xu ,  Rusheng Zhao ,  Hongxia Chen ,  Rui Xue ,  Juanjuan Qin ,  Zhenzhen Wang ,  Jiazhi Yao

IPC: A61K31/445 ,  A61K31/505 ,  C07D211/68 ,  C07D239/02 ,  C07D401/06

CPC classification number: C07D401/06

Abstract: Provided are N-[(4-hydroxypiperidin-4-yl)methyl]pyridin-2(1H)-one derivatives represented by formula I, stereoisomers, pharmaceutically acceptable salts or solvates thereof. The above compounds have the dual activities of 5-hydroxytryptamine 1A receptor ligand and selective serotonin reuptake inhibitor. The preparation methods of the above compounds, the uses of these compounds for the prevention or treatment of nervous system diseases related to 5-hydroxytryptamine system dysfunction and the pharmaceutical compositions containing these compounds are also provided.

Abstract translation: 提供由式I表示的N - [（4-羟基哌啶-4-基）甲基]吡啶-2（1H） - 酮衍生物，其立体异构体，药学上可接受的盐或溶剂合物。 上述化合物具有5-羟色胺1A受体配体和选择性5-羟色胺再摄取抑制剂的双重活性。 还提供了上述化合物的制备方法，这些化合物用于预防或治疗与5-羟色胺系统功能障碍有关的神经系统疾病的用途和含有这些化合物的药物组合物。